menu search

ALXO / ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction cancer. Final results from the ASPEN-06 study are expected to be released in Q2 2024, potentially leading to further gains for investors. ALXO also announced a cash raise of $55 million, reducing the need for a future cash raise and lowering the risk of dilution. Read More
Posted: Oct 9 2023, 00:38
Author Name: Seeking Alpha
Views: 111352

ALXO News  

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

By Seeking Alpha
October 9, 2023

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction can more_horizontal

ALX Oncology stock doubles on early data from phase II cancer trial

By Proactive Investors
October 3, 2023

ALX Oncology stock doubles on early data from phase II cancer trial

ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing th more_horizontal

ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

By Zacks Investment Research
August 10, 2023

ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled more_horizontal

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

By GlobeNewsWire
January 3, 2023

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immun more_horizontal


Search within

Pages Search Results: